Pastoris, O., Dossena, M., Foppa, P., Catapano, M., Arbustini, E., Bellini, O., Dal Bello, B., Minzioni, G., Ceriana, P., and Barzaghi, N
As a general principle, most DPP-4 inhibitors require dose reduction or avoidance in moderate-to-severe renal impairment
The pharmaceutical landscape has been transformed by Ozempic, which has led to a breakthrough in diabetes and weight management
The question is whether that buffer lasts as drugs get cheaper, side effects improve, and insurance coverage expands
What they can create is a sense of habitual reliance if you associate them with feeling your best